Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 7INDUSTRY 2NETWORK 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Fatigue 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Methylphenidate × Clear all
NCT01202734 2014-05-16

A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 1 Completed
10 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1

NCT00758407 2010-01-13

EMF

Medice Arzneimittel Pütter GmbH & Co KG

Phase 2/3 Completed
66 enrolled

Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡